Providing complex support in analytics and bioanalytics of large molecules, a BioPharma department’s capabilities help get more efficient drugs to patients and subsequently improve quality of life.

An essential part of QUINTA-ANALYTICA’s service portfolio, its BioPharma team offers comprehensive support via the testing of large, more complex pharmaceutical products such as peptides, proteins, monoclonal antibodies, and antibody-drug conjugates.

Led by Milan Madera, who has a strong background in characterization using chromatographic and mass spectrometric techniques, the dept. is equipped with modern high resolution/high mass accuracy LC-MS/MS, capillary electrophoresis designed for biopharma applications, and ELISA readers with a state-of-the-art MSD electrochemiluminescence platform which allows for immunogenicity testing of therapeutic drugs.

Despite being the newest dept. of Quinta, its operation in R&D, GMP, GLP, and GCP regimes help clients through the development and validations of methods not only for routine analysis of therapeutic products but also as bioanalytical support for preclinical and clinical testing.

If you’re looking for characterization of complex analytes or their quantification in various biological matrices, get in touch with Milan or the rest of the team today.

Additional News

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.